Antidiabetic tricyclic compounds

US9527875B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• William K. Hagmann · Westfield, US
• Ravi Nargund · East Brunswick Township, US
• Timothy A. Blizzard · Middletown, US
• Hubert Josien · Hoboken, US
• Purakkattle Biju · Piscataway, US
• Christopher W. Plummer · Hoboken, US
• Qun Dang · Westfield, US
• Bing Li · Towaco, US
• Derun Li · Dedham, US
• Linus S. Lin · Westfield, US
• Mingxiang Cui · Shanghai, CN
• Bin Hu · Mesa, US
• Jinglai Hao · Shanghai, CN
• Zhengxia Chen · Shanghai, CN

Key dates

• Filing date: Jul 31, 2013
• Grant date: Dec 27, 2016
• Expiry date: Jul 31, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.